Posted by Michael Wonder on 04 May 2019
Seattle Genetics announces progress in expanding Adcentis (brentuximab vedotin) indications in Canada
3 May 2019 - Health Canada approves Adcetris in combination with AVD chemotherapy for the treatment of previously untreated Hodgkin's lymphoma based on positive Phase 3 ECHELON-1 clinical trial results.
Seattle Genetics today announced that Health Canada has approved the supplemental new drug submission that expands the use of ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine and dacarbazine) chemotherapy in patients with previously untreated Stage IV Hodgkin's lymphoma.
The approval is based on positive results of the phase 3 ECHELON-1 clinical trial that compared ADCETRIS plus AVD to ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine).
